Reportlinker Adds Daiichi Sankyo Co., Ltd: PharmaVitae Profile

NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Daiichi Sankyo Co., Ltd: PharmaVitae Profile

http://www.reportlinker.com/p0110533/Daiichi-Sankyo-Co-Ltd-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Daiichi Sankyo's performance against key rivals in the prescription pharmaceutical sector

*Assess the importance of Daiichi Sankyo's olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) to the company's outlook

*Evaluate the prospects of the company's recent acquisition, Ranbaxy

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company Introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Daiichi Sankyo: PharmaVitae forecasts at a glance 8

Strategic insight 9

Olmesartan franchise central to Daiichi Sankyo's growth over 2002-14 9

Successful prevention of generic threat 9

Ranbaxy acquisition to drive growth over 2008-14 9

SWOT analysis 11

Strengths 11

Successful line extensions have propelled Daiichi Sankyo to a leading position in the antihypertensives market 11

Strong connections with US pharma 12

Weaknesses 12

Lack of portfolio diversity 12

Opportunities 12

Ranbaxy acquisition provides significant growth prospects and opportunities for streamlining 12

Effient to provide significant royalty income 13

Threats 13

Ranbaxy regulatory scrutiny by FDA 13

TABLE OF CONTENTS 14

Table of figures 16

Chapter 3 Quarterly update 17

Latest comment 17

Q3 2009 17

Q2 2009 17

Biota: new flu drug may present Tamiflu alternative 17

Prasugrel: a flawed approval? 18

Q1 2009 20

Latest prescription pharma product news 21

Q1 2010 21

Q4 2009 21

Q3 2009 22

Q2 2009 23

Q1 2009 24

Q4 2008 25

Latest corporate news 26

Q4 2009 26

Q3 2009 26

Q2 2009 26

Q1 2009 26

Q4 2008 26

Chapter 4 Company Introduction 28

Key findings 28

Background 29

M&A history 29

Ranbaxy acquisition 29

Zenotech: opportunity in biopharmaceuticals 30

Current corporate structure 31

Chapter 5 Company sales 32

Key findings 32

Prescription pharmaceutical sales and growth rate analysis, 2002-14 33

Product analysis 35

Product analysis, 2002-08 36

Product analysis, 2008-14 38

Therapy area analysis 42

Geographic analysis 44

Launch/core/expiry analysis 47

Explanation of launch/core/expiry analysis 47

Launch analysis, 2008-14 48

Core analysis, 2008-14 49

Expiry analysis, 2008-14 50

Generics analysis, 2008-14 51

Launch/core/expiry configuration, 2008-14 52

Molecule type analysis 53

Externalization analysis 55

Chapter 6 Appendix 58

Abbreviations 58

Exchange rates 59

About Datamonitor 60

About Datamonitor Healthcare 60

Datamonitor consulting 60

Disclaimer 62

LIST OF TABLES

Table 1: Daiichi Sankyo - PharmaVitae forecasts at a glance 8

Table 2: Daiichi Sankyo product portfolio overview ($m), 2002-08 36

Table 3: Daiichi Sankyo product portfolio overview ($m), 2008-14 38

Table 4: Daiichi Sankyo prescription pharmaceutical sales by therapy area ($m), 2008-14 43

Table 5: Daiichi Sankyo prescription pharmaceutical sales by geographic region ($m), 2008-14 45

Table 6: Daiichi Sankyo launch portfolio overview ($m), 2008-14 48

Table 7: Daiichi Sankyo core portfolio overview ($m), 2008-14 49

Table 8: Daiichi Sankyo expiry portfolio overview ($m), 2008-14 50

Table 9: Daiichi Sankyo generics portfolio overview ($m), 2008-14 51

Table 10: Daiichi Sankyo prescription pharmaceutical sales by molecule type ($m), 2008-14 54

Table 11: Daiichi Sankyo prescription pharmaceutical sales by source ($m), 2008-14 56

Table 12: Exchange rates, 2009 59

LIST OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Daiichi Sankyo's financial performance ($m), 2002-14 7

Figure 4: Daiichi Sankyo sales according to key growth drivers ($m), 2002-14, 10

Figure 5: Daiichi Sankyo SWOT analysis 11

Figure 6: Current corporate structure 31

Figure 7: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 33

Figure 8: Key product sales ($m), 2002-14 35

Figure 9: Daiichi Sankyo key sales growth drivers and resistors ($m), 2002-08 37

Figure 10: Daiichi Sankyo key sales growth drivers and resistors ($m), 2008-14 40

Figure 11: Daiichi Sankyo prescription pharmaceutical sales by therapy area ($m), 2002-14 42

Figure 12: Daiichi Sankyo prescription pharmaceutical sales by geographic region ($m), 2002-14 44

Figure 13: Daiichi Sankyo launch/core/expiry configuration ($m), 2008-14 52

Figure 14: Daiichi Sankyo prescription pharmaceutical sales by molecule type ($m), 2002-14 53

Figure 15: Daiichi Sankyo prescription pharmaceutical sales by source ($m), 2002-14 55

To order this report:

Pharmaceutical Industry: Daiichi Sankyo Co., Ltd: PharmaVitae Profile

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.